{"id":"seroquel-ir-quetiapine-fumarate","safety":{"commonSideEffects":[{"rate":"18-27%","effect":"Somnolence/sedation"},{"rate":"9-16%","effect":"Dry mouth"},{"rate":"10-18%","effect":"Dizziness"},{"rate":"13-19%","effect":"Headache"},{"rate":"8-10%","effect":"Constipation"},{"rate":"5-23%","effect":"Weight gain"},{"rate":"6-8%","effect":"Tachycardia"},{"rate":"7-9%","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL3188993","moleculeType":"Small molecule","molecularWeight":"883.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quetiapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which reduces psychotic symptoms and stabilizes mood. It also has activity at other receptors including histamine H1 and adrenergic receptors, contributing to its sedating properties and broader psychiatric effects.","oneSentence":"Quetiapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:34.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic and depressive episodes)"},{"name":"Major depressive disorder (as adjunctive therapy)"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT04373317","phase":"PHASE4","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-24","conditions":"Parkinson's Disease Psychosis","enrollment":358},{"nctId":"NCT04310579","phase":"PHASE1","title":"Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-06-15","conditions":"Hypercapnia, Ventilatory Depression","enrollment":55},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT00206115","phase":"PHASE3","title":"SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenic Disorder","enrollment":535},{"nctId":"NCT00206128","phase":"PHASE3","title":"Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00554658","phase":"PHASE4","title":"Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2008-03","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT00926393","phase":"PHASE4","title":"Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Bipolar Depression","enrollment":139},{"nctId":"NCT00486798","phase":"PHASE3","title":"FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":""},{"nctId":"NCT00832221","phase":"PHASE1","title":"Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Depression","enrollment":10},{"nctId":"NCT00702676","phase":"PHASE1","title":"Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Healthy Volunteers","enrollment":63},{"nctId":"NCT00254787","phase":"PHASE2","title":"Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-06","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT00838032","phase":"PHASE4","title":"Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2008-08","conditions":"Acute Schizophrenia","enrollment":70},{"nctId":"NCT00457899","phase":"PHASE3","title":"Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Schizophrenia, Schizoaffective Disorders, Psychotic Disorders","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Seroquel IR - quetiapine fumarate","genericName":"Seroquel IR - quetiapine fumarate","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Quetiapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute manic and depressive episodes), Major depressive disorder (as adjunctive therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}